Antithrombotic Treatment of Atrial Fibrillation: Insights from AHA 2023 Studies

2023-11-17 19:22:01

Jean-Claude Deharo discusses 3 studies presented at AHA 2023 in the antithrombotic treatment of atrial fibrillation, namely:

ARTESIA which compares the effectiveness of apixaban vs aspirin for the prevention of stroke in patients with subclinical atrial fibrillation, NOAH-AFNET6 which focuses on anticoagulation with edoxaban vs placebo in patients with episodes of ‘AHRE of a duration greater than or equal to 24 hours, and AZALEA-TIMI 71 relating to abelacimab, a new inhibitor of factor XI/XIa vs rivaroxaban in patients with atrial fibrillation.

So what should we learn from these studies? Jean-Claude Deharo reveals the key elements in this video!

Access exclusive Cardio-online content!

Subscribe

Access interviews Watch session videos Discuss clinical cases And more… I subscribe!
1700270293
#AHA #Conference #News

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.